Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 3120.

https://doi.org/10.1182/blood-2019-124349

Published: 2019

Journal Articles

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Salmon Manier, Meletios A. Dimopoulos, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Michel Delforge, Katja C. Weisel, MD, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Bruno Costa, Suzanne Robinson, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 3122.

https://doi.org/10.1182/blood-2019-124557

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Hans C. Lee, MD, Sikander Ailawadhi, MD, Cristina Gasparetto, MD, Sundar Jagannath, Robert M. Rifkin, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne I. Wagner, PhD, James L. Omel, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 3129.

https://doi.org/10.1182/blood-2019-126205

Published: 2019

Journal Articles

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Sundar Jagannath, MD, Mohit Narang, MD, Sikander Ailawadhi, Robert M Rifkin, MD, Howard R Terebelo, DO, Kathleen Toomey, MD, Brian GM Durie, MD, James W Hardin, PhD, Cristina J Gasparetto, MD, Lynne Wagner, PhD, James Omel, MD, Shankar Srinivasan, PhD MBA, Amani Kitali, MPH, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2018) 132 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2018-99-110877

Published: 2018

Journal Articles

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Cristina J. Gasparetto, MD, Rafat Abonour, MD, Sundar Jagannath, MD, Brian G. M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne Wagner, PhD, Shankar Srinivasan, PhD, Amani Kitali, MBA, MPH, E. Dawn Flick, MPH, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3101.

https://doi.org/10.1182/blood.V130.Suppl_1.3101.3101

Published: 2017

Journal Articles

Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

Aaron Seth Rosenberg, MD, Thierry Facon, MD, Safiya Abouzaid, MPH, PharmD, Shankar Srinivasan, PhD, Weiyuan Chung, Kejal Parikh, BSPharm, MS, Joseph Tuscano, MD

Blood (2017) 130 (Supplement 1): 3113.

https://doi.org/10.1182/blood.V130.Suppl_1.3113.3113

Published: 2017

Journal Articles

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Sundar Jagannath, MD, Robert M. Rifkin, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Ahmed YoussefAgha, PhD, Amani Kitali, MBA, MPH, Gail Larkins, RN, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2017) 130 (Supplement 1): 3122.

https://doi.org/10.1182/blood.V130.Suppl_1.3122.3122

Published: 2017

Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1812.

https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812

Published: 2017

Journal Articles

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Howard R. Terebelo, DO, Rafat Abonour, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Lihua Yue, PhD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 1842.

https://doi.org/10.1182/blood.V130.Suppl_1.1842.1842

Published: 2017

Journal Articles

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Mohit Narang, MD, Rafat Abonour, MD, Brian G. M. Durie, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Shankar Srinivasan, PhD, E. Dawn Flick, MPH. ScD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3156.

https://doi.org/10.1182/blood.V130.Suppl_1.3156.3156

Published: 2017

Journal Articles

Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)

Sikander Ailawadhi, Gail Larkins, RN, MBA, Weiyuan Chung, Shankar Srinivasan, PhD, Amit Agarwal, MD PhD

Blood (2017) 130 (Supplement 1): 3428.

https://doi.org/10.1182/blood.V130.Suppl_1.3428.3428

Published: 2017

Journal Articles

Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect ® MM Disease Registry

Rafat Abonour, MD, Brian G.M. Durie, MD, Sundar Jagannath, MD, Jatin J. Shah, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Amani Kitali, MPH, PMP, Craig Gibson, PhD, Shankar Srinivasan, PhD, Arlene S. Swern, PhD, Robert M. Rifkin, MD

Blood (2016) 128 (22): 537.

https://doi.org/10.1182/blood.V128.22.537.537

Published: 2016

Journal Articles

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety

David S. Siegel, MD PhD, Gary J. Schiller, MD, Kevin W. Song, MD, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Fred J. Reu, Ehsan Malek, MD, Jorge L Mouro, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Syed Rizvi, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 4497.

https://doi.org/10.1182/blood.V128.22.4497.4497

Published: 2016

Journal Articles

Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect ® MM Registry

Robert M. Rifkin, MD, Rafat Abonour, MD, Brian G.M. Durie, MD, Cristina J. Gasparetto, MD, Sundar Jagannath, MD, Mohit Narang, MD, Jatin J. Shah, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, Amani Kitali, MPH, PMP, Faiza Zafar, BSc, MBBS, Shankar Srinivasan, PhD, James W. Hardin, PhD

Blood (2016) 128 (22): 4489.

https://doi.org/10.1182/blood.V128.22.4489.4489

Published: 2016

Journal Articles

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin J. Shah, MD, Rafat Abonour, MD, Brian G M Durie, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Robert M. Rifkin, MD

Blood (2014) 124 (21): 2106.

https://doi.org/10.1182/blood.V124.21.2106.2106

Published: 2014

Journal Articles

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Robert M. Rifkin, MD, Rafat Abonour, MD, Jatin J. Shah, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Jane Jie Lu, MS, Laurie Kenvin, BSN, RN, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4749.

https://doi.org/10.1182/blood.V124.21.4749.4749

Published: 2014

Journal Articles

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Rafat Abonour, MD, Jatin J. Shah, M.D., Brian Durie, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Jayesh Mehta, MD, Mohit Narang, MD, Sachdev P Thomas, MD, Kathleen Toomey, MD, Kristen A Sullivan, MBA, CCRA, Shankar Srinivasan, PhD, Yasir Nagarwala, MD, Robert M Rifkin, MD

Blood (2013) 122 (21): 3207.

https://doi.org/10.1182/blood.V122.21.3207.3207

Published: 2013

NARROW

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)

Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect ® MM Disease Registry

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety

Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect ® MM Registry

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only